Claims for Patent: 10,487,145

Summary for Patent: 10,487,145

Title:	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
Abstract:	Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
Inventor(s):	Imran; Mir (Los Altos Hills, CA)
Assignee:	Rani Therapeutics, LLC (San Jose, CA)
Application Number:	15/192,915
Patent Claims:	1. A method for delivering infliximab to a patient, said method comprising: advancing a solid dosage of infliximab shaped as a tissue penetrating member into an intestinal wall after oral ingestion by the patient to penetrate the solid dosage infliximab into the intestinal wall, wherein infliximab is released into the blood stream from the solid dosage infliximab in the intestinal wall. 2. The method of claim 1, wherein the infliximab released into the blood stream from the solid dosage infliximab reaches a C.sub.max a shorter time period than a time period to achieve a C.sub.max for an extravascularly injected dose of infliximab. 3. The method of claim 2, wherein a t.sub.max for the infliximab released from the solid dosage infliximab is less than 80% of a t.sub.max for the extravascularly injected dose of infliximab. 4. The method of claim 2, wherein a t.sub.max for the infliximab released from the solid dosage infliximab is less than 50% of a t.sub.max for the extravascularly injected dose of Infliximab. 5. The method of claim 2, wherein a t.sub.max for the infliximab released from the solid dosage infliximab is less than 30% of a t.sub.max for the extravascularly injected dose of Infliximab. 6. The method of claim 2, wherein a t.sub.max for the infliximab released from the solid dosage infliximab is less than 10% of a t.sub.max for the extravascularly injected dose of Infliximab. 7. The method of claim 1, wherein the tissue penetrating member is inserted into a wall of the small intestine. 8. The method of claim 1, wherein the tissue penetrating member is orally delivered to the intestine in a swallowable capsule. 9. The method of claim 8, wherein penetrating the solid dosage of infliximab into the intestinal wall comprises operably coupling the solid dosage of infliximab to a delivery means having a first configuration wherein the solid dosage of infliximab is within the capsule and a second configuration wherein the solid dosage of infliximab is advanced out of the capsule and into the intestinal wall. 10. The method of claim 9, wherein penetrating the solid dosage infliximab into the intestinal wall comprises expanding at least one expandable balloon from the first to the second configuration. 11. The method of claim 1, wherein the solid dosage infliximab comprises a biodegradable material which degrades within the intestinal wall to release infliximab into the blood stream. 12. The method of claim 11, wherein the biodegradable material comprises PLGA (polylactic-co-glycolic add), a sugar or maltose. 13. The method of claim 1, wherein the solid dosage infliximab comprises at least one pharmaceutical excipient. 14. The method of claim 13, wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant. 15. The method of claim 14, wherein the hinder comprises polyethylene glycol (PEG). 16. The method of claim 1, wherein a weight percent of infliximab in the solid dosage infliximab comprises between about 8 to 12%. 17. The method of claim 1, wherein a dose of infliximab in the tissue penetrating member is in a range from about 1 to 10 mg. 18. The method of claim 17, wherein a dose of infliximab in the tissue penetrating member is about 5 mg. 19. The method of claim 1, further comprising retaining the solid dosage of infliximab within the intestinal wall after insertion. 20. The method of claim 19, wherein retaining comprises anchoring at least one of a barb or an inverse taper shape of the solid dosage of infliximab in the intestinal tissue. 21. The method of claim 1, wherein penetrating the solid dosage of infliximab comprises applying a force to the solid dosage of infliximab to advance the solid dosage of infliximab completely into the intestinal wall. 22. The method of claim 1, wherein the solid dosage infliximab produces a release of infliximab to produce a t.sub.1/2 of about 40 days. 23. The method of claim 1, wherein a C.sub.max achieved by delivering the solid dosage infliximab into the intestinal wall is at least 10 to 100 times greater than a C.sub.max achieved when the solid dosage infliximab is delivered orally without insertion into the intestinal wall. 24. The method of claim 1, wherein the tissue penetrating member has a pointed tip.

Details for Patent 10,487,145

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2030-12-23